Exosome-based cancer vaccine for prevention of lung cancer

Shuhan Meng; Aaron G Whitt; Bryce F Stamp; John W Eaton; Chi Li; Kavitha Yaddanapudi

doi:10.21037/sci-2022-030

Exosome-based cancer vaccine for prevention of lung cancer

Stem Cell Investig. 2023 Jan 9:10:2. doi: 10.21037/sci-2022-030. eCollection 2023.

Authors

Shuhan Meng^{1

2}, Aaron G Whitt^{1

2}, Bryce F Stamp^{3

4}, John W Eaton^{1

2

5}, Chi Li^{1

2

5}, Kavitha Yaddanapudi^{3

4

6}

Affiliations

¹ Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, USA.
² Experimental Therapeutics Program, Brown Cancer Center, University of Louisville, Louisville, KY, USA.
³ Department of Surgery, Division of Immunotherapy, University of Louisville, Louisville, KY, USA.
⁴ Immuno-Oncology Program, Brown Cancer Center, University of Louisville, Louisville, KY, USA.
⁵ Department of Medicine, University of Louisville, Louisville, KY, USA.
⁶ Department of Microbiology and Immunology, University of Louisville, Louisville, KY, USA.

Abstract

Background: Our earlier work has shown that a unique stem cell-based vaccine that comprises of murine embryonic stem cells (ESCs) and murine fibroblasts expressing the immunostimulant granulocyte-macrophage colony stimulating factor (GM-CSF) successfully protects mice from the outgrowth of an implantable form of murine lung cancer. The use of live ESCs raises the potential risks of inducing teratomas and autoimmunity. We have attempted to improve the safety and utility of this prophylactic vaccine by employing exosomes derived from murine ESCs engineered to produce GM-CSF (ES-exo/GM-CSF vaccine).

Methods: We have previously reported that ES-exo/GM-CSF immunization does protect mice from the outgrowth of an implantable form of murine lung cancer. Here, we have investigated the cancer prevention efficacy of ES-exo/GM-CSF vaccine in an experimental metastasis model of murine lung cancer, in which Lewis lung carcinoma (LLC) cells were administered into female C57BL/6 mice (8 weeks of age) through tail vein injection and subsequently LLC tumors were established in lungs.

Results: Our objective is to test the anti-cancer efficacy of ES-exo/GM-CSF vaccine in a mouse model of metastatic lung cancer. Our studies indicate that vaccination of mice with ES-exo/GM-CSF vaccine inhibited the growth of metastatic lung tumors. ES-exo/GM-CSF vactionation reduced lung tumor burden from 1.86% in non-vaccinated, LLC-challenged mice to 0.036% in corresponding vacinnated mice. Importantly, control exosomes without GM-CSF failed to provide protection against metastasized pulmonary tumors. The efficacy of ES-exo/GM-CSF vaccination was associated with a decrease in the frequencies of tumor-infiltrating immunosuppressive immune cells, including T regulatory cells, myeloid derived suppressor cells (MDSCs) and tumor-associated macrophages, as well as an increase in effector cytokine production from intra-tumoral CD8⁺ T cells.

Conclusions: Overall, our research provides a novel strategy for developing a cell-free prophylactic vaccine against lung tumors.

Keywords: Exosome; lung cancer; metastasis; vaccine.

Abstract

Grants and funding